Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trialKohei Shitara, Hyun Cheol Chung, Kei Muro et al.|The Lancet|2018Cited by 1.3k
Bevacizumab plus oxaliplatin-based chemotherapy as adjuvant treatment for colon cancer (AVANT): a phase 3 randomised controlled trialAimery de Gramont, Paulo M. Hoff, Eric Van Cutsem et al.|The Lancet Oncology|2012Cited by 526
Immune checkpoint inhibitors for POLE or POLD1 proofreading-deficient metastatic colorectal cancerMargherita Ambrosini, Filippo Pietrantonio, Benoı̂t Rousseau et al.|Annals of Oncology|2024Cited by 73
Assessing the prognostic value of carcinoembryonic antigen levels in stage I and II colon cancerOfer Margalit, Ben Boursi, Ronac Mamtani et al.|European Journal of Cancer|2018Cited by 48
Consensus statement on essential patient characteristics in systemic treatment trials for metastatic colorectal cancer: Supported by the ARCAD GroupKaitlyn K.H. Goey, Miriam Koopman, Halfdan Sørbye et al.|European Journal of Cancer|2018Cited by 34